Ketamine Treatment for PTSD and MDD in TBI

M

Minneapolis Veterans Affairs Health Care System (VAHCS)

Status and phase

Not yet enrolling
Phase 2

Conditions

PTSD, Post Traumatic Stress Disorder
Traumatic Brain Injury
Major Depressive Disorder

Treatments

Drug: Midazolam
Drug: IV ketamine

Study type

Interventional

Funder types

Other U.S. Federal agency

Identifiers

NCT06228391
1770474-4

Details and patient eligibility

About

The goal of this clinical trial is to examine the use of sedative ketamine to treat depression and post-traumatic stress disorder (PTSD) in Veterans with mild to moderate traumatic brain injury (TBI). The main questions it aims to answer are: * Efficacy of ketamine to reduce symptoms of depression and/or PTSD * Safety of ketamine to treat depression and/or PTSD in TBI Participants will be randomly assigned to receive either ketamine or midazolam (active placebo) twice a week for 3 weeks. During participation, subjects will be interviewed, have lab tests, and complete rating scales, and questionnaires.

Enrollment

40 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Willingness/able to sign informed consent.
  • Able to read and write in English.
  • Male or female Veterans aged 18-55 years old.
  • Remote history of TBI mild-moderate that is ≥12 weeks post-injury (chronic period) that met at minimum the 2021 VA/DoD Clinical Practice Guideline for the Management and Rehabilitation of Post-Acute Mild Traumatic Brain Injury (i.e., new onset or worsening of at least one of the following clinical signs immediately following the event: loss or decreased of consciousness, period of posttraumatic amnesia, period of being dazed and confused, and neurologic deficits).
  • Lifetime history of treatment resistance to at least one adequate trial of an antidepressant as determined by the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (MGH-ATRQ).
  • FDA-approved antidepressant, trazodone, atypical neuroleptic, prazosin, or clonidine with stable treatment, as determined by the study clinician, for at least 4 weeks prior to randomization. Following randomization, changes to doses may be allowable at the investigator's discretion

Exclusion criteria

  • Ketamine treatment within the last 6 months

    • Lifetime history of psychosis-related disorder, current episode of mania/hypomania/mixed assessed by the Mini-International Neuropsychiatric Interview (MINI 7.0 for DSM-5).
    • History of penetrating head wounds or severe traumatic brain injury (Glasgow Coma Scale <9; loss of consciousness >24hr; post-traumatic amnesia>7 days).
    • Severe substance and/or alcohol use disorder (DSM-5-TR) within six months of initial assessment; presence of illicit drugs (except cannabis) by positive urine toxicology at screening.
    • Intellectual disability or pervasive developmental disorder; dementia of any type.
    • Any disorder that, based on the Principal Investigator's judgement, would increase risk (e.g., unstable cardiac conditions) or protocol adherence (e.g., severe personality disorder).
    • For women: pregnancy (confirmed by lab test), initiation of female hormonal treatments within 3 months of screening, or inability/ unwillingness to use a medically accepted contraceptive method during the study. Women who are surgically sterile or have been post-menopausal for at least 1 year will not be excluded
    • At screening, resting blood pressure (sitting or supine) lower than 90/60 or higher than 150/90, or resting heart rate lower than 45/min or higher than 100/min.
    • Imminent risk of suicidal/homicidal ideation and/or behavior with intent and/or plan.
    • Concurrent participation in a cognitive rehabilitation program, however patient will have a TBI clinician involved in directed services.
    • Subjects on a prohibited medication: monoamine oxidase inhibitors, memantine, long acting benzodiazepines (i.e., Chlordiazepoxide, Diazepam, Flurazepam)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

40 participants in 2 patient groups

Ketamine
Experimental group
Description:
Twice a week ketamine IV 0.5 mg/kg
Treatment:
Drug: IV ketamine
Midazolam
Active Comparator group
Description:
Twice a week midazolam IV 0.045 mg/kg
Treatment:
Drug: Midazolam

Trial contacts and locations

1

Loading...

Central trial contact

Paulo Shiroma, MD; Seth Dsiner, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems